Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T; Arbeitsgemeinschaft Internistische Onkologie, Germany. Moehler M, et al. Among authors: ebert mp. Ann Oncol. 2010 Jan;21(1):71-7. doi: 10.1093/annonc/mdp269. Epub 2009 Jul 15. Ann Oncol. 2010. PMID: 19605504 Free article. Clinical Trial.
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer.
Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; German Arbeitsgemeinschaft Internistische Onkologie (AIO). Moehler M, et al. Among authors: ebert mp. Eur J Cancer. 2011 Jul;47(10):1511-20. doi: 10.1016/j.ejca.2011.04.006. Epub 2011 May 9. Eur J Cancer. 2011. PMID: 21561763 Clinical Trial.
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H, Schade-Brittinger C, Müller HH, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM; Arbeitsgemeinschaft Internistische Onkologie (AIO). Fensterer H, et al. Among authors: ebert mp. Ann Oncol. 2013 Oct;24(10):2576-2581. doi: 10.1093/annonc/mdt270. Epub 2013 Jul 29. Ann Oncol. 2013. PMID: 23897705 Free article. Clinical Trial.
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M; Working Group of Internal Oncology. Moehler M, et al. Among authors: ebert mp. Eur J Cancer. 2014 Dec;50(18):3125-35. doi: 10.1016/j.ejca.2014.09.013. Epub 2014 Oct 15. Eur J Cancer. 2014. PMID: 25446376 Free article. Clinical Trial.
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE, Goker E, De Dosso S, Kneba M, Yalcin S, Overkamp F, Schlegel F, Dommach M, Rohrberg R, Steinmetz T, Bulitta M, Strumberg D. Schultheis B, et al. Among authors: ebert mp. Ann Oncol. 2017 Oct 1;28(10):2429-2435. doi: 10.1093/annonc/mdx343. Ann Oncol. 2017. PMID: 28961832 Free article. Clinical Trial.
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Heinemann V, et al. Among authors: ebert mp. Br J Cancer. 2013 Mar 5;108(4):766-70. doi: 10.1038/bjc.2013.62. Epub 2013 Feb 14. Br J Cancer. 2013. PMID: 23412098 Free PMC article. Clinical Trial.
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study.
Li M, Meindl-Beinker NM, Maenz M, Betge J, Schulte N, Zhan T, Hofheinz RD, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Bauer H, Ebert MP, Haertel N. Li M, et al. Among authors: ebert mp. J Geriatr Oncol. 2024 Sep;15(7):101838. doi: 10.1016/j.jgo.2024.101838. Epub 2024 Aug 3. J Geriatr Oncol. 2024. PMID: 39097500 Free article. Clinical Trial.
Gastric Cancer: New Drugs - New Strategies.
Schulte N, Ebert MP, Härtel N. Schulte N, et al. Among authors: ebert mp. Gastrointest Tumors. 2014 May;1(4):180-94. doi: 10.1159/000380786. Epub 2015 Mar 27. Gastrointest Tumors. 2014. PMID: 26674336 Free PMC article. Review.
304 results